Genetic and Pharmacological Inhibition of Dimethylarginine Dimethylaminohydrolase 1 Is Protective in Endotoxic Shock | Zendy

Manasi Nandi | Zendy; Peter D. Kelly | Zendy; Belén Torondel | Zendy; Zhen Wang | Zendy; Anna Starr | Zendy; Yue Ma | Zendy; Philip Cunningham | Zendy; Raymond Stidwill | Zendy; James Leiper | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Genetic and Pharmacological Inhibition of Dimethylarginine Dimethylaminohydrolase 1 Is Protective in Endotoxic Shock

Author(s) -

Manasi Nandi,

Peter D. Kelly,

Belén Torondel,

Zhen Wang,

Anna Starr,

Yue Ma,

Philip Cunningham,

Raymond Stidwill,

James Leiper

Publication year - 2012

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.112.300232

Subject(s) - lipopolysaccharide , septic shock , shock (circulatory) , pharmacology , circulatory system , asymmetric dimethylarginine , chemistry , biology , medicine , sepsis , biochemistry , arginine , amino acid

The overproduction of vascular NO contributes toward the circulatory collapse observed in patients with septic shock. Dimethylarginine dimethylaminohydrolase (DDAH), which has 2 isoforms, metabolizes asymmetrically methylated arginines (asymmetric mono- or di-methylarginine), endogenously produced NO synthase inhibitors. We wished to investigate whether reducing DDAH1 activity, using genetic and pharmacological approaches, is protective during lipopolysaccharide-induced endotoxic shock.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research